Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 525-528

  Osaki, Rie ^a   Nishimura, Takashi ^a   Shioya, Makoto ^a   Takeuchi, Takayuki ^b   Okumura, Yoshiaki ^c   Nakahara, Tamio ^b   Bamba, Shigeki ^a   Nakajo, Shinobu ^b   Fujiyama, Yoshihide ^a   Andoh, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Notogawa Hospital   (Japan)

^c Social Insurance Shiga Hospital   (Japan)

Author keywords

Hepatitis C; Interferon; Interleukin 28

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; SEROTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ALLELES; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C; HETEROZYGOTE; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; SEROTYPING;

HEPATITIS C VIRUS;

EID: 84855715351     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.655     Document Type: Article

References (25)

1. Thompson AJ, Muir AJ, Sulkowski MS, et al: Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139: 120-129; e118, 2010.
2. Ochi H, Maekawa T, Abe H, et al: IL-28B predicts response to chronic hepatitis C therapy . fine-mapping and replication study in Asian populations. J Gen Virol 92: 1071-1081, 2011.
3. Hadziyannis SJ and Koskinas JS: Differences in epidemiology, liver disease and treatment response among HCV genotypes. Hepatol Res 29: 129-135, 2004. (Pubitemid 38780127)
4. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y and Onji M: Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 45: 86-94, 2010.
5. Kurosaki M, Tanaka Y, Nishida N, et al: Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 54: 439-448, 2011.
6. Yasui K, Harano Y, Mitsuyoshi H, et al: Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. J Gastroenterol 45: 95-104, 2010.
7. Hadziyannis SJ, Sette H Jr, Morgan TR, et al: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
8. Nakagawa M, Sakamoto N, Ueyama M, et al: Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol 45: 656-665, 2010.
9. Iino S, Ichida F, Sakuma A and Suzuki H: A randomized clinical trial with natural interferon-alpha monotherapy for 24 or 48 weeks on patients with chronic hepatitis C having genotype 1b infection in high viral titers. Hepatol Res 24: 338-345, 2002. (Pubitemid 36002122)
10. Enomoto N, Sakuma I, Asahina Y, et al: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81, 1996. (Pubitemid 26017933)
11. Akuta N, Suzuki F, Kawamura Y, et al: Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 79: 1686-1695, 2007. (Pubitemid 47479887)
12. Izumi N, Asahina Y and Kurosaki M: Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat 2010: 703602, 2010.
13. Tanaka Y, Nishida N, Sugiyama M, et al: Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105.1109, 2009.
14. Ge D, Fellay J, Thompson AJ, et al: Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401, 2009.
15. Ahlenstiel G, Booth DR and George J: IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol 45: 903-910, 2010.
16. Osaki R, Nishimura T, Takeuchi T, et al: Interleukin-28 polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy. Exp Ther Med 2: 715-718, 2011.
17. Livak KJ: Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14: 143-149, 1999.
18. Ray Kim W: Global epidemiology and burden of hepatitis C. Microbes Infect 4: 1219-1225, 2002.
19. Akuta N, Suzuki F, Sezaki H, et al: Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48: 372-380, 2005. (Pubitemid 41003622)
20. McCarthy JJ, Li JH, Thompson A, et al: Replicated association between an IL28B gene variant and a sustained response to pegylated interferonand ribavirin. Gastroenterology 138: 2307-2314, 2010.
21. Rauch A, Kutalik Z, Descombes P, et al: Genetic variation in IL28B is associated with chronic hepatitis C and treatmeant failure - a genome-wide association study. Gastroenterology 138: 1338-1345, 2010.
22. Yu ML, Dai CY, Huang JF and Chuang WL: Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure. Hepatology 48: 1019.1020, 2008.
23. Tsubota A, Fujise K, Namiki Y and Tada N: Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol 17: 419-432, 2011.
24. McHutchison JG, Lawitz EJ, Shiffman ML, et al: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580-593, 2009.
25. Marcello T, Grakoui A, Barba-Spaeth G, et al: Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898, 2006. (Pubitemid 44958521)